欢迎访问上海芮晖化工科技有限公司官方网站！
咨询电话: +86-21-31433387|邮箱: sales@rechemscience.com
产品分类
联系我们
| 电话： | +86-21-31433387 |
| +86-15618786686 | |
| Email: | sales@rechemscience.com |
| info@rechemscience.com | |
| QQ: | 1369748377 |
| Skype: | rechem@outlook.com |
| 目录号 | 产品名称 | 产品描述 |
| R10157 | AZD9291 Intermediate1 | Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi |
| R10158 | AZD9291 Intermediate2 | Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi |
| R10261 | CDC0032 Intermediate | |
| R10275 | Omarigliptin; MK3102 Intermediate1 | Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor wit |
| R10276 | Omarigliptin; MK3102 Intermediate2 | Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor wit |
| R10277 | AZD9291Intermediate3 | Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi |
| R10278 | AZD9291Intermediate4 | Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi |
| R10279 | AZD9291Intermediate5 | Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi |
| R10280 | CAL101 Intermediate1 | CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM |
| R10281 | CAL101 Intermediate2 | CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM |
| R10282 | CAL101 Intermediate3 | CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM |
| R10284 | Nintedanib; BIBF1120 Intermediate2 | Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, |
| R10285 | Nintedanib; BIBF1120 Intermediate3 | Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, |
| R10286 | Nintedanib; BIBF1120 Intermediate4 | Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, |
| R10289 | TR700; DA7157; Torezolid Intermediate1 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10290 | TR700; DA7157; Torezolid Intermediate2 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10291 | TR700; DA7157; Torezolid Intermediate3 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10292 | TR700; DA7157; Torezolid Intermediate4 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10293 | TR700; DA7157; Torezolid Intermediate5 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10294 | TR700; DA7157; Torezolid Intermediate6 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10297 | Afatinib BIBW2992 Intermediate1 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10298 | Afatinib BIBW2992 Intermediate2 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10299 | Afatinib BIBW2992 Intermediate3 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10300 | Afatinib BIBW2992 Intermediate4 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10301 | Afatinib BIBW2992 Intermediate5 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
